AtriCure (ATRC) opened 2026 with Q1 revenue of US$141.2 million and basic EPS of roughly US$0.00, supported by net income of US$0.1 million, against a trailing 12 month loss of US$4.6 million on revenue of US$552.2 million. The company has seen quarterly revenue move from US$123.6 million in Q1 2025 to US$141.2 million in Q1 2026, while basic EPS has shifted from a loss of US$0.14 to a small profit. This sets up a quarter where margins appear tight but directionally less pressured than the recent loss making trend.

See our full analysis for AtriCure.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely followed stories about AtriCure, and where those narratives might need a rethink based on the data.

Revenue growth, profits still thin

• Quarterly revenue rose from US$123.6 million in Q1 2025 to US$141.2 million in Q1 2026, while net income moved from a loss of US$6.7 million to a small profit of about US$0.1 million, leaving trailing 12 month net loss at US$4.6 million on US$552.2 million of revenue.
• What bullish investors highlight as strengthening adoption and room for margin improvement is partly echoed here. However, the thin Q1 profit sits alongside a trailing 12 month loss and past multi year loss growth of 17.4% a year. The optimistic view on earnings growth and margin expansion still has to contend with a business that is only just breaking even on a quarterly basis.

🐂 AtriCure Bull Case

Unprofitable on TTM, yet priced for growth

• The stock trades at about US$28.01 against a DCF fair value of roughly US$1.62 and an analyst price target of US$47.00, while the company remains unprofitable over the trailing 12 months with a net loss of US$4.6 million.
• Bears point out that the current price sits well above the DCF fair value figure, even as losses have compounded at 17.4% a year over five years. They also note that this sits awkwardly next to the TTM loss and rich implied P/E needed to reach the US$47.00 target, which together make the cautious narrative on valuation and profit quality look well grounded in the supplied numbers.
  • The gap between the US$28.01 price and US$1.62 DCF fair value is very large, so anyone leaning on that DCF will likely see limited support for aggressive upside.
  • At the same time, the data describe earnings forecasts that require earnings growth of 46.14% a year and a move to profitability within three years, so the bearish concern is that a lot of improvement is already implied while the company still reports a trailing 12 month loss.

🐻 AtriCure Bear Case

P/S discount versus peers

• AtriCure trades on a P/S of 2.6x compared with a peer average of 3.7x and a US Medical Equipment industry average of 2.7x, according to the supplied data.
• Consensus style commentary in the data flags this P/S discount as a possible positive, yet sets it against ongoing trailing 12 month losses and the wide gap to the US$1.62 DCF fair value. As a result, the relative sales based valuation support is balanced by the need for the business to move from a five year pattern of widening losses to the forecast 46.14% annual earnings growth that would justify the analyst target of US$47.00.
  • The 2.6x P/S is lower than both peer and industry averages, which aligns with investors who see AtriCure as cheaper on sales than many alternatives.
  • However, the company still reported a trailing 12 month loss of US$4.6 million, so that P/S discount exists alongside an unprofitable recent track record rather than an already established earnings base.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AtriCure on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of cautious and optimistic takes feels incomplete, do not wait for the next update to form an opinion. Review the numbers, stress test your thesis, and see how those potential bright spots stack up in the 3 key rewards

Explore Alternatives

AtriCure is still working through a trailing 12 month loss, thin quarterly profits, and a wide gap between its share price and DCF fair value.

If that mix of fragile profitability and valuation tension feels uncomfortable, compare it with companies screened for stronger fundamentals and potential mispricing by checking out the 45 high quality undervalued stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.